Merck (MRK) ended the recent trading session at $117.17, demonstrating a -0.05% swing from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily loss of 0.19%.

Merck & Co. said a European Medicines Agency panel recommended expanded approval of the drugmaker's blockbuster cancer treatment Keytruda in two types of gynecologic cancers.

If you want to avoid toxic fertilizers and insecticides, skip those with organophosphates, a toxic group of chemicals that can kill large dogs in even small doses, according to the Merck Veterinary ...

How To Buy Merck & Company Shares By now you're likely curious about how to participate in the market for Merck & Co MRK – be it to purchase shares, or even attempt to bet against the company.

Is Merck a good buy right now? Investors can buy Merck's stock at a fairly reasonable multiple of 15 times next year's earnings (based on analyst estimates). It's a reasonably valued stock at a ...

Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...

We recently compiled a list of the 10 Best Cancer Stocks To Buy Now. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other cancer stocks.

On Tuesday, TD (TSX:TD) Cowen reaffirmed its confidence in Merck & Co Inc (NYSE:MRK), maintaining a Buy stock rating with a steady price target of $140.00. The firm's analysis included a reassessment ...